Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience

Mediwake Heshani; Morris Kirk; Curley Cameron; Butler Jason; Kennedy Glen

首页> 外文期刊>Internal medicine journal >Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience

【24h】

Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience

机译：使用Brentuximab Vedotin作为抢救治疗前异种干细胞移植复发/难治性CD30阳性淋巴增殖障碍：单一中心经验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The role of brentuximab peri-allogeneic transplantation in patients with relapsed and/or refractory CD30 positive lymphomas remains poorly defined.

机译：背景：Brentuximab Peri-同种异体移植在复发和/或难治性CD30阳性淋巴瘤患者中的作用仍然定义差。

著录项

来源
《Internal medicine journal》 |2017年第5期|共5页
作者
Mediwake Heshani; Morris Kirk; Curley Cameron; Butler Jason; Kennedy Glen;
展开▼
作者单位

Royal Brisbane &

Womens Hosp Canc Care Serv Brisbane Qld Australia;

Royal Brisbane &

Womens Hosp Canc Care Serv Brisbane Qld Australia;

Royal Brisbane &

Womens Hosp Canc Care Serv Brisbane Qld Australia;

Royal Brisbane &

Womens Hosp Canc Care Serv Brisbane Qld Australia;

Royal Brisbane &

Womens Hosp Canc Care Serv Brisbane Qld Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词
Hodgkin lymphoma; anaplastic large cell lymphoma; allogeneic stem cell transplantation;

机译：Hodgkin淋巴瘤;一个促进的大细胞淋巴瘤;同种异体干细胞移植;

相似文献

外文文献
中文文献
专利

1. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience [J] . Mediwake Heshani, Morris Kirk, Curley Cameron, Internal medicine journal . 2017,第5期

机译：使用Brentuximab Vedotin作为抢救治疗前异种干细胞移植复发/难治性CD30阳性淋巴增殖障碍：单一中心经验
2. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis [J] . Zinzani Pier Luigi, Chen Robert, Armand Philippe, Leukemia and lymphoma . 2020,第3a4期

机译：Pembrolizumab单药治疗初级耐火经典霍奇金淋巴瘤淋巴瘤，后者复制后复制后爆发性干细胞移植和/或Brentuximab Vedotin治疗：Keynote-087亚组分析
3. A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric hodgkin lymphoma patients before and after stem cell transplantation [J] . Nurdan Ta?y?ld?z, Hikmet Gül?ah Tany?ld?z, Emel ünal, The Turkish journal of pediatrics. . 2019,第5期

机译：在干细胞移植之前和之后，患有Brentuximab Vedotin的靶向抗菌蛋白的抗蛋白患者患者
4. Arsenic Salvage Is Superior to Chemotherapy and Bone Marrow Transplantation for Relapsed Acute promyelocytic Leukemia: Ten Years of Experience from Hong Kong [C] . W.Y. Au, R. Liang, A.K.W. Lie, European Haematology Association . 2002

机译：砷救生优于化疗和骨髓移植复发急性突出细胞细胞白血病：来自香港的十年经验
5. Posttraumatic stress disorder and sub-syndromal trauma symptoms in cancer patients treated with autologous hematopoietic stem cell transplant and standard dose chemotherapy. [D] . Gourvitz, Ross L. 2008

机译：自体造血干细胞移植和标准剂量化疗治疗的癌症患者的创伤后应激障碍和综合征下创伤症状。
6. Alectinib an anaplastic lymphoma kinase (ALK) inhibitor as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin [O] . Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, 2019

机译：Alectinib一种间变性淋巴瘤激酶（ALK）抑制剂可作为同种异体干细胞移植的桥梁适用于对化疗和brentuximab vedotin难治的ALK阳性间变性大细胞淋巴瘤患者
7. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy [O] . Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, 2018

机译：Brentuximab Vedotin在不适合干细胞移植或多蛋白化疗的复发/难治性霍奇金淋巴瘤患者中的前瞻性研究

Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience

摘要

著录项

相似文献

相关主题

期刊订阅